XML 64 R19.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Business segment information | 9 Months Ended
--- | ---
Sep. 30, 2014
Segment Reporting [Abstract] |
Business segment information | 14. Business segment information The Company manages the business by four strategic business units (“SBUs”), which are comprised of BioStim, Biologics, Extremity Fixation, and Spine Fixation supported by Corporate activities. These SBUs represent the segments for which the Chief Executive Officer, who is also our Chief Operating Decision Maker (“CODM”), reviews financial information and makes resource allocation decisions among business units. The primary metric used by the CODM in managing the Company is net margin, which is defined as gross profit less sales and marketing expense. The Company neither discretely allocates assets, other than goodwill, to its operating segments nor evaluates the operating segments using discrete asset information. Accordingly, segment information has been prepared based on four SBUs reporting segments. These four segments are discussed below. BioStim The BioStim SBU manufactures, distributes, and provides support services for market leading devices that enhance bone fusion. These Class III medical devices are indicated as an adjunctive, noninvasive treatment to improve fusion success rates in the cervical and lumbar spine as well as a therapeutic treatment for non-spine fractures that have not healed (non-unions). The devices utilize Orthofix’s patented pulsed electromagnetic field (“PEMF”) technology which is supported by strong basic mechanism of action data in the scientific literature as well as strong level one randomized controlled clinical trials in the medical literature. Current research and clinical studies are also underway to identify potential new clinical indications. Biologics Biologics provides a portfolio of regenerative products that allow physicians to successfully treat a variety of spinal and orthopedic conditions. This SBU specializes in the marketing of regeneration tissue forms. Biologics markets its tissues through a network of distributors, sales representatives and affiliates to supply to hospitals, doctors, and other healthcare providers, primarily in the U.S. The Company’s partnership with Musculoskeletal Transplant Foundation (“MTF”) allows the Company to exclusively market Trinity Evolution® and Trinity ELITE® tissue forms for musculoskeletal defects to enhance bony fusion as well as VersaShield™ for which we have non-exclusive rights. Extremity Fixation The Extremity Fixation SBU offers products that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. This SBU specializes in the design, development, and marketing of the Company’s orthopedic products used in fracture repair, deformity correction and bone reconstruction. Extremity Fixation distributes its products through a network of distributors, sales representatives, and affiliates. This SBU uses both direct and distributor sales representatives to sell orthopedics products to hospitals, doctors, and other health providers, globally. Spine Fixation The Spine Fixation SBU specializes in the design, development and marketing of a broad portfolio of implant products used in surgical procedures of the spine. Spine Fixation distributes its products through a network of distributors and affiliates. This SBU uses distributor sales representatives to sell spine products to hospitals, doctors and other healthcare providers, globally. Corporate Corporate activities are comprised of the operating expenses of Orthofix International N.V. and its holding company subsidiaries, along with activities not necessarily identifiable within the four SBUs. The accounting policies of the segments are the same as those described in the business segment information found in Note 13, “Business segment information” to the Consolidated Financial Statements included in the 2013 Form 10-K/A. The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to the new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution®, Trinity ELITE® and Versashield™ in the Biologics segment.
|  | External Net Sales by SBU |
|  | Three Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2014 |  |  | 2013 |  |  | Reported Growth |  |  | Constant Currency Growth |
|  |  |  |  | (Restated) |  |  |  |  |  |  |
BioStim |  | $ | 38,285 |  |  | $ | 30,654 |  |  |  | 25 | % |  |  | 25 | %
Biologics |  |  | 13,856 |  |  |  | 13,216 |  |  |  | 5 | % |  |  | 5 | %
Extremity Fixation |  |  | 27,636 |  |  |  | 24,705 |  |  |  | 12 | % |  |  | 9 | %
Spine Fixation |  |  | 21,217 |  |  |  | 23,231 |  |  |  | (9 | )% |  |  | (9 | )%
Total Net Sales |  | $ | 100,994 |  |  | $ | 91,806 |  |  |  | 10 | % |  |  | 9 | %
|  | External Net Sales by SBU |
|  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2014 |  |  | 2013 |  |  | Reported Growth |  |  | Constant Currency Growth |
|  |  |  |  | (Restated) |  |  |  |  |  |  |
BioStim |  | $ | 114,937 |  |  | $ | 105,828 |  |  |  | 9 | % |  |  | 9 | %
Biologics |  |  | 40,718 |  |  |  | 39,816 |  |  |  | 2 | % |  |  | 2 | %
Extremity Fixation |  |  | 82,005 |  |  |  | 74,112 |  |  |  | 11 | % |  |  | 9 | %
Spine Fixation |  |  | 64,333 |  |  |  | 71,969 |  |  |  | (11 | )% |  |  | (11 | )%
Total Net Sales |  | $ | 301,933 |  |  | $ | 291,725 |  |  |  | 3 | % |  |  | 3 | %
The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2014 |  |  | 2013 |  |  | 2014 |  |  | 2013 |
|  |  |  |  | (Restated) |  |  |  |  |  | (Restated) |
Net margin: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BioStim |  | $ | 16,442 |  |  | $ | 13,397 |  |  | $ | 49,168 |  |  | $ | 48,614 |
Biologics |  |  | 6,504 |  |  |  | 6,737 |  |  |  | 19,500 |  |  |  | 18,463 |
Extremity Fixation |  |  | 8,361 |  |  |  | 7,089 |  |  |  | 21,952 |  |  |  | 17,980 |
Spine Fixation |  |  | 3,958 |  |  |  | 913 |  |  |  | 11,147 |  |  |  | 5,796 |
Corporate |  |  | (537 | ) |  |  | (470 | ) |  |  | (1,411 | ) |  |  | (1,376 | )
Total net margin |  |  | 34,728 |  |  |  | 27,666 |  |  |  | 100,356 |  |  |  | 89,477 |
General and administrative |  |  | 18,814 |  |  |  | 12,933 |  |  |  | 53,643 |  |  |  | 46,355 |
Research and development |  |  | 6,572 |  |  |  | 6,361 |  |  |  | 18,818 |  |  |  | 20,653 |
Amortization of intangible assets |  |  | 508 |  |  |  | 616 |  |  |  | 1,753 |  |  |  | 1,725 |
Costs related to the accounting review and restatement |  |  | 2,326 |  |  |  | 2,664 |  |  |  | 12,959 |  |  |  | 2,664 |
Impairment of goodwill |  |  | — |  |  |  | 19,193 |  |  |  | — |  |  |  | 19,193 |
Operating income |  | $ | 6,508 |  |  | $ | (14,101 | ) |  | $ | 13,183 |  |  | $ | (1,113 | )

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration